Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Gastroenterology

Background:

• Methylnaltrexone (MNTX) is a peripherally restricted opioid antagonist that targets mu-opioid receptors.
• MNTX reduces gastrointestinal opioid side effects while preserving central analgesia.
• Low oral bioavailability of MNTX necessitates improved oral formulation strategies.

Purpose of the Study:

• To develop and evaluate an oral formulation of MNTX with enhanced bioavailability.
• To assess the pharmacokinetic profile of a methylnaltrexone-phosphatidylcholine (MNTX-PC) complex in rats.

Main Methods:

• A methylnaltrexone-phosphatidylcholine (MNTX-PC) complex was synthesized and characterized.
• Oral bioavailability of MNTX-PC was determined in rats following a single oral dose (250 mg/kg).
• Plasma MNTX concentrations were quantified using LC/MS/MS over a 9-hour period.

Main Results:

• The MNTX-PC formulation exhibited two plasma concentration peaks at 120 and 180 minutes.
• Compared to MNTX in solution, MNTX-PC showed a 410% relative bioavailability.
• Key pharmacokinetic parameters for MNTX-PC included Tmax of 180 min, Cmax of 1083.7 ± 293.9 ng/mL, and T½ of 496 min.

Conclusions:

• The MNTX-PC formulation significantly enhances the oral bioavailability of methylnaltrexone.
• This complex represents a promising strategy for improving oral MNTX delivery.
• Further research may explore clinical applications of this enhanced formulation.